Compare ProShares Ultra Silver ETF (AGQ) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Amylx Pharmaceuticals Inc — how do they compare? ProShares Ultra Silver ETF trades at $81.5, while Amylx Pharmaceuticals Inc trades at $24.05 (market cap $2.64B). The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | AMLX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $24.19 |
52-Week Low | $49.73 | $7.82 |
Market Cap | — | $2.64B |
Enterprise Value | — | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGQ, the ProShares Ultra Silver ETF, trades at $83.06, up 1.44% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights its volatility, surging 9.39% on silver rallies but facing structural decay concerns due to 2x daily leverage. Financial ratios are unavailable as it is an ETF tracking silver futures.
Outlook is highly speculative, offering amplified silver exposure with significant risk. Opportunities exist if silver prices rise, but risks include leverage decay, volatility-driven losses, and silver market downturns. Investors should weigh aggressive gains against potential rapid declines.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
